<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Medullary thyroid cancer: Surgical treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Medullary thyroid cancer: Surgical treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Medullary thyroid cancer: Surgical treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            R Michael Tuttle, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas S Ross, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with medullary thyroid cancer (MTC) can be cured only by complete resection of the thyroid tumor and any local and regional metastases. For patients with residual or recurrent disease after primary surgery or for those with distant metastases, the most appropriate treatment (surgery, chemotherapy, or radiotherapy) is less clear.
        </p>
        <p>
         This topic review will discuss the role of surgery as primary therapy and the approaches to treating patients with persistent or recurrent MTC after surgery. The approach outlined below is largely in agreement with American Thyroid Association (ATA) and National Comprehensive Cancer Network (NCCN) guidelines [
         <a href="#rid1">
          1,2
         </a>
         ]. Recommendations for the timing of thyroidectomy in children with
         <em>
          RET
         </em>
         mutations and the role of chemotherapy in the treatment of MTC are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">
          "Approach to therapy in multiple endocrine neoplasia type 2", section on 'Preventive surgery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PREOPERATIVE EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Newly diagnosed patients with medullary thyroid cancer (MTC) should be staged both biochemically and radiologically (
         <a class="graphic graphic_algorithm graphicRef102747" href="/z/d/graphic/102747.html" rel="external">
          algorithm 1
         </a>
         ). This evaluation is reviewed briefly below and in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7848.html" rel="external">
          "Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
         The following tests should be performed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcitonin
         </strong>
         <strong>
          and CEA
         </strong>
         – Measurement of serum calcitonin and carcinoembryonic antigen (CEA) to determine whether they are produced by the tumor, and if so, as a baseline for comparison with results obtained after surgery. Among patients with either sporadic or familial tumors, those with higher preoperative serum calcitonin concentrations have larger tumors and are less likely to have normal serum concentrations after surgery than those with lower preoperative values [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ultrasonography
         </strong>
         – Ultrasonography of the neck to assess for local and regional disease. Additional imaging is necessary for patients with local lymph node metastases or with preoperative serum basal calcitonin &gt;500 pg/mL (indicating high risk of local or distant metastatic disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Analysis for pathogenic
         </strong>
         <strong>
          <em>
           RET
          </em>
         </strong>
         <strong>
          variants
         </strong>
         – Germline
         <em>
          RET
         </em>
         mutation analysis to determine which patients with apparently sporadic MTC have unsuspected germline
         <em>
          RET
         </em>
         mutations (the underlying defect in multiple endocrine neoplasia type 2 [MEN2]) and therefore heritable disease. Germline mutational analysis may be performed pre- or postoperatively. Even when performed preoperatively, the results are rarely known prior to surgery. The presence or absence of a germline mutation has little impact on the initial surgical approach.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening for hyperparathyroidism and pheochromocytoma
         </strong>
         – Measurement of serum calcium and either plasma fractionated metanephrines or 24-hour urinary excretion of metanephrine and catecholamines to assess for hyperparathyroidism and pheochromocytoma, respectively. This testing should be performed in all patients who have either unknown
         <em>
          RET
         </em>
         mutation status or a germline
         <em>
          RET
         </em>
         mutation. In patients with negative
         <em>
          RET
         </em>
         mutation analysis and no family history of MEN2-related diseases, such testing typically is not required.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          SURGICAL APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H458875">
         <span class="h2">
          MTC confined to the neck
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total thyroidectomy rather than unilateral lobectomy is the preferred surgical approach. Up to 10 percent of patients with sporadic medullary thyroid cancer (MTC) and all patients with inherited MTC have bilateral or multifocal disease [
         <a href="#rid1">
          1
         </a>
         ]; in addition, the latter all have premalignant diffuse C cell hyperplasia. (See
         <a class="medical medical_review" href="/z/d/html/7848.html" rel="external">
          "Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">
          "Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"
         </a>
         .)
        </p>
        <p>
         The extent of cervical lymph node dissection depends on the findings on preoperative ultrasound as well as intraoperative identification of lymph node metastases.
        </p>
        <p>
         The types of surgical procedures are described in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">
          "Thyroidectomy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">
          "Differentiated thyroid cancer: Surgical treatment", section on 'Approach to lymph node dissection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H970707894">
         <span class="h3">
          No ultrasound evidence of cervical lymph node involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with MTC confined to the neck and no evidence of involved cervical lymph nodes on preoperative ultrasound, we routinely perform prophylactic bilateral dissection of the central lymph node compartment without prophylactic lateral neck dissection. Prophylactic central neck dissection is not required in patients with small intrathyroidal MTCs with a preoperative calcitonin &lt;20 pg/mL, as metastatic lymph nodes are exceedingly rare in this circumstance [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         For patients with intraoperative evidence of central cervical lymph node involvement, dissection of the involved lateral neck compartment is also performed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central lymph node dissection
         </strong>
         – Prophylactic bilateral dissection of the central lymph node compartment (from the hyoid bone to the innominate veins and medial to the jugular veins) is the preferred initial treatment for most patients [
         <a href="#rid1">
          1
         </a>
         ]. MTC usually spreads to the central neck nodes. In one study of 101 consecutive patients with MTC (and no previous surgery), lymph node metastases to the central compartment were seen in approximately 50 percent of both sporadic (n = 54) and hereditary (n = 47) cases [
         <a href="#rid5">
          5
         </a>
         ]. Metastatic spread to central neck lymph nodes is exceedingly rare, however, if the preoperative basal calcitonin is &lt;20 pg/mL [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a retrospective series, patients treated with total thyroidectomy with central neck lymph node dissection required fewer reoperations than those receiving lesser procedures [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lateral lymph node dissection
         </strong>
         – Whether or not to perform lateral neck dissections in the absence of ultrasonographically identifiable lymph node metastases as part of the primary surgery remains controversial. The lateral jugular and mediastinal nodes should be carefully evaluated intraoperatively, followed by modified neck and/or mediastinal dissections only if positive nodes are identified. Although we do not routinely advise lateral neck dissections in the absence of identifiable lymph node metastases (regardless of the serum calcitonin level), dissection of the ipsilateral lateral lymph node compartment is performed for patients with intraoperative evidence of central lymph node involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study, ipsilateral lateral lymph node metastases were found in 10 percent of patients with no central node involvement, 77 percent of patients with one to three central nodes, and 98 percent of patients with more than four central nodes; contralateral lateral lymph node metastases were found in 4.9 percent of patients with no central nodes, 38 percent of patients with one to nine central nodes, and 77 percent with more than nine central nodes [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The American Thyroid Association (ATA) guidelines committee could not achieve a consensus agreement on this topic but did recommend that prophylactic lateral neck dissections "may be considered based on serum calcitonin levels" [
         <a href="#rid1">
          1
         </a>
         ]. Some members recommended against routine prophylactic lateral neck dissections if there was no evidence of disease on preoperative neck ultrasound. Other members utilized preoperative calcitonin values to guide the extent of prophylactic neck dissections by recommending prophylactic ipsilateral central and ipsilateral lateral neck dissection for patients with basal serum calcitonin values &gt;20 pg/mL and prophylactic dissection of uninvolved contralateral lateral neck compartments for serum calcitonin &gt;200 pg/mL [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The primary argument in favor of routine use of prophylactic lateral neck dissection in patients with a preoperative basal calcitonin level of ≤1000 pg/mL is that at least one-half of them will achieve biochemical cure (calcitonin &lt;10 pg/mL) [
         <a href="#rid4">
          4
         </a>
         ]. Since a biochemical cure is associated with 98 percent 10-year survival and approximately 3 to 4 percent recurrence rate, proponents of prophylactic lateral lymph node dissection argue that the benefits outweigh the additional risks and complications associated with routine use of prophylactic lateral neck dissections when done by experienced surgeons [
         <a href="#rid10">
          10-12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The counter argument is that long-term survival rates are also excellent in patients with a biochemical incomplete response to initial therapy (abnormal postoperative calcitonin in the absence of structural disease progression), ranging from 90 to 100 percent at 10 years of follow-up, with the highest survival rates seen in patients with intrathyroidal MTC without evidence for local or distant metastases [
         <a href="#rid10">
          10,13,14
         </a>
         ]. Thus, the excellent outcomes attributed to more aggressive upfront resection of the lateral compartment subclinical lymph nodes may be more related to the underlying biology of the disease rather than to our therapeutic interventions. Furthermore, routine use of prophylactic lateral neck dissections will expose patients to additional morbidity, particularly knowing that most of these surgeries are not done by high-volume, very experienced surgeons.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus, it remains unclear if there is truly a survival benefit from more aggressive upfront lymph node dissection done in an effort to achieve an initial excellent response to therapy as opposed to a more measured surgical intervention, recognizing that some patients will have a biochemical incomplete response that may or may not require additional therapy in the future based on follow-up imaging and the trend in calcitonin/carcinoembryonic antigen (CEA) values.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3012010854">
         <span class="h3">
          Ultrasound evidence of cervical lymph node involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with MTC involving the thyroid and known cervical lymph nodal involvement preoperatively, total thyroidectomy with bilateral central compartment dissection and dissection of the involved lateral neck compartment(s) is the preferred initial treatment. In addition to compartment-oriented dissection of the clinically involved ipsilateral neck, prophylactic neck dissection of uninvolved contralateral neck compartments should also be considered in patients with a basal calcitonin level greater than 200 pg/mL if there is no evidence of distant metastases [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H458921">
         <span class="h2">
          Locally advanced or metastatic MTC
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with locally advanced or metastatic disease, total thyroidectomy with resection of involved lymph node compartments is recommended in most patients. Since the goals of surgery are largely palliative in this setting, a less aggressive surgical approach to the thyroid primary and to lymph node dissection in the central and lateral neck compartments may be warranted in order not to impair speech, swallowing, parathyroid function, and shoulder mobility [
         <a href="#rid1">
          1
         </a>
         ]. In the presence of grossly invasive disease, more extended procedures with resection of involved neck structures may be appropriate in properly selected patients, but function-preserving (speech, swallowing) approaches are preferred. Disfiguring radical neck dissections do not improve prognosis and are not indicated. The surgical approach should be individualized based upon the patient's wishes, life expectancy, and other medical comorbidities [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The role of
         <em>
          RET
         </em>
         -targeted kinase inhibitors prior to thyroidectomy as neoadjuvant therapy for locally advanced or metastatic
         <em>
          RET
         </em>
         -mutated MTC is under investigation [
         <a href="#rid15">
          15-18
         </a>
         ]. The goal of neoadjuvant therapy is to decrease the size of a locally advanced tumor in order to make the surgery more effective with less morbidity. Preliminary data suggest that
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          selpercatinib
         </a>
         prior to surgical intervention can be associated with a decrease in tumor size and a likely improvement in preservation of major structures. However, pathology reports demonstrate fibroadipose tissue deposits, extranodal extension, and fibrosis, which makes the surgery technically challenging [
         <a href="#rid16">
          16
         </a>
         ]. A clinical trial evaluating the efficacy and safety of selpercatinib prior to surgical intervention for the treatment of RET-altered thyroid cancer is ongoing [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H458970">
         <span class="h2">
          MTC diagnosed after lobectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If medullary thyroid cancer (MTC) is diagnosed postoperatively after a unilateral lobectomy, management options include completion thyroidectomy (eg, removal of the remaining thyroid tissue) or observation with monitoring of serum calcitonin levels. Because patients with hereditary MTC uniformly have bilateral disease, all patients with hereditary MTC should have a completion thyroidectomy.
        </p>
        <p>
         The approach in patients with sporadic MTC is less certain, and there are few data to guide management decisions. The incidence of bilateral disease in patients with sporadic MTC is low, ranging from 0 to 9 percent [
         <a href="#rid1">
          1,4,20
         </a>
         ]. Therefore, completion thyroidectomy is not routinely indicated in patients without a germline
         <em>
          RET
         </em>
         mutation. However, we do perform completion thyroidectomy in sporadic MTC if the postoperative serum calcitonin is elevated above the upper normal value of the reference range or if there is imaging evidence of persistent disease in the thyroid or regional lymph nodes [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          POSTOPERATIVE MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2716443">
         <span class="h2">
          Monitor for postoperative complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immediately after surgery, the patient should be monitored closely for the development of hypoparathyroidism or injury to either the recurrent or superior laryngeal nerves. These complications are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">
          "Differentiated thyroid cancer: Surgical treatment", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">
          "Thyroidectomy", section on 'Calcium supplementation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Thyroxine therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroxine (
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         , T4) therapy should be started immediately after surgery; an appropriate initial dose is 1.6 mcg/kg of body weight (ie, approximately 0.075 to 0.15 mg daily). The adequacy of therapy should be evaluated clinically and by measurement of serum thyroid-stimulating hormone (TSH) in six weeks. The goal of T4 therapy should be to restore and maintain a euthyroid state; suppression of serum TSH concentrations is not indicated in patients with medullary thyroid cancer (MTC), because C cells are not TSH responsive. Similarly, adjuvant therapy with radioiodine is contraindicated because the tumor cells do not concentrate iodine [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2716852">
         <span class="h2">
          Assessment of tumor samples for somatic mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Somatic mutations in
         <em>
          RET
         </em>
         ,
         <em>
          HRAS
         </em>
         ,
         <em>
          KRAS
         </em>
         , or, rarely,
         <em>
          NRAS
         </em>
         can be identified in tumors of patients with sporadic MTC. In some [
         <a href="#rid22">
          22-24
         </a>
         ], but not other [
         <a href="#rid25">
          25
         </a>
         ], studies, tumors with an identifiable
         <em>
          RET
         </em>
         mutation had a more aggressive course than those without a mutation. Nonetheless, we agree that somatic mutational analysis of tumor samples is not required as part of routine clinical care [
         <a href="#rid1">
          1
         </a>
         ]. However, molecular characterization of the primary tumor (or metastatic foci) is recommended in patients with progressive metastatic disease that warrants systemic therapy in order to identify tumors that harbor a somatic
         <em>
          RET
         </em>
         mutation (which would suggest treatment with a specific RET inhibitor). (See
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2716429">
         <span class="h1">
          SUBSEQUENT MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         After thyroidectomy, it is important to evaluate patients to determine if surgery was curative [
         <a href="#rid10">
          10
         </a>
         ]. We measure serum calcitonin and carcinoembryonic antigen (CEA) to assess for cure. Subsequent management depends upon these values.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Serum calcitonin and CEA measurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum calcitonin and carcinoembryonic antigen (CEA) should be measured two to three months after surgery to detect the presence of residual disease. Patients who have normal serum CEA and undetectable serum calcitonin values are considered biochemically cured and have the best prognosis [
         <a href="#rid10">
          10,13,26,27
         </a>
         ]. Among those in one large series who were biochemically cured, the five-year recurrence rate was only 5 percent [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The timing of measurement of serum calcitonin after surgery is important because the serum calcitonin concentration falls slowly in some patients, with the nadir not being reached for several months [
         <a href="#rid28">
          28
         </a>
         ]. However, in patients who are surgically cured, calcitonin levels begin to rapidly decline within the first postoperative hour [
         <a href="#rid29">
          29
         </a>
         ], often achieving undetectable levels within the first few postoperative days in patients destined to achieve a biochemical cure [
         <a href="#rid30">
          30-34
         </a>
         ]. Therefore, serum calcitonin measurements as early as a few days to weeks after surgery can provide early evidence of biochemical remission in many patients, but elevated levels in the immediate postoperative period do not necessarily indicate persistent disease.
        </p>
        <p class="headingAnchor" id="H2716597">
         <span class="h3">
          Undetectable calcitonin and normal CEA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with undetectable calcitonin levels and carcinoembryonic antigen (CEA) values within the normal reference range after surgery (ie, biochemically cured), subsequent follow-up should include (
         <a class="graphic graphic_algorithm graphicRef102746" href="/z/d/graphic/102746.html" rel="external">
          algorithm 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination twice yearly for two years and then yearly thereafter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measurement of serum calcitonin and CEA levels twice yearly for two years and then yearly thereafter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neck ultrasound 3 to 12 months postoperatively (depending on the extent of lymph node involvement prior to surgery) to establish a baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional imaging is not required unless the calcitonin or CEA values rise during follow-up.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9088928">
         <span class="h3">
          Persistent hypercalcitoninemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         A high basal serum calcitonin value three or more months after surgery is presumptive evidence of residual disease. Thirty to 55 percent of patients with palpable medullary thyroid cancer (MTC) or nonpalpable but macroscopic MTC who undergo attempted curative resection have persistently high serum calcitonin concentrations [
         <a href="#rid5">
          5,6,11,35,36
         </a>
         ].
        </p>
        <p>
         The prognosis for patients with postoperative hypercalcitoninemia depends primarily upon the patient's age and the extent of disease at the time of initial surgery [
         <a href="#rid6">
          6,11,13,37-39
         </a>
         ]. In a series of 899 patients with MTC (57 percent sporadic), the 10-year survival in the patients with postoperative hypercalcitoninemia (57 percent of the total group) was 70 percent compared with 98 percent in patients who were biochemically cured [
         <a href="#rid11">
          11
         </a>
         ]. Younger age at surgery and absence of lymph node involvement were predictive of biochemical cure.
        </p>
        <p>
         Further evaluation and management depend upon the magnitude of the elevation in the serum calcitonin concentration (
         <a class="graphic graphic_algorithm graphicRef102746" href="/z/d/graphic/102746.html" rel="external">
          algorithm 2
         </a>
         ). In addition, for patients with persistent elevation, assessment of calcitonin and CEA doubling times provides sensitive markers for progression and aggressiveness of metastatic MTC [
         <a href="#rid40">
          40,41
         </a>
         ]. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcitonin &lt;150 pg/mL
         </strong>
         – Calcitonin values that are detectable but less than 150 pg/mL two to six months after surgery usually indicate persistent locoregional disease in the neck. Therefore, neck ultrasound with or without additional cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI] of the neck) should be performed to evaluate for the presence of persistent macroscopic metastatic disease. Serum calcitonin and CEA are measured every 6 to 12 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If imaging is positive, meticulous dissection of all cytologically confirmed local and regional nodal tissue can be considered if there is no evidence of disease outside of the neck or mediastinum. As in the primary surgical setting, compartment-oriented neck dissections are recommended when surgery is performed for cytologically confirmed locoregional disease. More focused neck dissections may be appropriate in previously dissected neck compartments. However, outside of centers experienced in managing these patients, only those with overt disease in the neck and no distant metastases should undergo neck dissection in this setting. (See
         <a class="local">
          'Management of persistent/recurrent disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If imaging is negative and the serum calcitonin values measured every three to six months remain stable, neck ultrasound is usually performed every 6 to 12 months for two to three years, then less often during long-term follow-up. Additional imaging should be considered in patients with rising calcitonin and CEA values, with the type and frequency of testing based on both the magnitude and rate of rise of these biochemical markers. (See
         <a class="local">
          'Small volume, asymptomatic'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcitonin ≥150 pg/mL
         </strong>
         – Calcitonin values that remain ≥150 pg/mL two to six months after surgery increase the likelihood that the patient may have distant metastases [
         <a href="#rid1">
          1,2
         </a>
         ]. Therefore, patients with postoperative calcitonin levels that are ≥150 pg/mL should undergo neck ultrasound and additional imaging (CT or MRI of neck, chest, and abdomen; bone scan or bone MRI in patients suspected of having skeletal metastases) to identify possible distant metastases. The liver is the most common site of metastases in patients with MTC, occurring in approximately 45 percent of patients with advanced disease [
         <a href="#rid1">
          1
         </a>
         ]. Liver metastases are best identified with three-phase contrast-enhanced liver CT or contrast-enhanced liver MRI. Other sites include bone, brain, and lung.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If imaging is negative, monitoring with physical examination, measurement of serum calcitonin and CEA, and evaluation of the neck with ultrasonography should continue. The frequency of repeating imaging studies will be dependent on the magnitude and rate of rise of the calcitonin and CEA values. As an example, patients with stable postoperative serum calcitonin values in the 150 to 300 pg/mL range are usually followed with yearly neck ultrasound for several years, reserving repeat cross-sectional imaging (neck, chest, abdomen) to look for distant metastases in those patients with rising calcitonin or CEA values.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) scans are considered only when the serum calcitonin is higher than 500 to 1000 pg/mL. In one report of 28 patients with MTC, PET had a sensitivity of 78 percent when calcitonin was &gt;1000 pg/mL but failed to detect disease if calcitonin was &lt;500 pg/mL [
         <a href="#rid42">
          42
         </a>
         ]. Alternative PET tracers such as fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) [
         <a href="#rid43">
          43-46
         </a>
         ] and gallium-68 (68Ga) radiolabeled somatostatin analogue peptides (DOTATATE, DOTATOC, and DOTANOC) [
         <a href="#rid46">
          46-52
         </a>
         ] have been studied and appear to be more sensitive for disease detection than FDG PET scanning. The precise role for these alternative tracers is being defined.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Radionuclide bone imaging can be helpful in selected cases when cross-sectional imaging fails to identify the source of the persistent hypercalcitoninemia [
         <a href="#rid53">
          53-55
         </a>
         ]. Attempted localization of disease by catheterization of the hepatic veins, both internal jugular veins, and the innominate veins, with measurements of serum calcitonin before and after calcium stimulation or laparoscopic examination of the liver, is rarely considered and only if these findings would impact clinical management [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If imaging is positive, treatment depends upon the site of disease and may include surgical resection and/or external beam radiation therapy (EBRT). (See
         <a class="local">
          'Management of persistent/recurrent disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2716622">
         <span class="h2">
          Management of persistent/recurrent disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment options for patients with recurrent/residual disease include observation/active surveillance, surgical resection, EBRT, and other directed therapies (such as radiofrequency ablation, cryoablation, embolization) or systemic therapies. In the past, patients with identifiable residual or recurrent MTC were operated on routinely. However, despite routine lymphadenectomy or excision of palpable tumor, their serum calcitonin concentrations often did not normalize after surgery [
         <a href="#rid57">
          57
         </a>
         ]. This has led to a more critical evaluation of the need for and timing of therapeutic interventions and reevaluation of the role of cautious observation in properly selected patients. The following approach to management of residual disease is based upon observational studies and clinical experience.
        </p>
        <p>
         The recommended treatment approach for persistent/recurrent disease depends upon a variety of clinical factors, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whether or not the disease can be localized
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The volume of disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The precise location(s) of the metastatic disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whether or not the disease is causing symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate (or likelihood) of clinically significant structural disease progression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          RET
         </em>
         mutational status
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18452937">
         <span class="h3">
          Small volume, asymptomatic
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biochemical evidence of disease without structural correlate
         </strong>
         – Patients with detectable calcitonin and/or abnormal CEA values without structurally identifiable disease are best followed with observation. The extent and frequency of cross-sectional imaging is dependent on the magnitude and doubling time of calcitonin and CEA (see
         <a class="local">
          'Persistent hypercalcitoninemia'
         </a>
         above). In the absence of structurally identifiable disease, we do not suggest additional surgery or systemic therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the absence of gross residual disease, we also do not recommend routine use of postoperative EBRT as adjuvant therapy, even if the postoperative calcitonin and CEA values are abnormal. We reserve adjuvant EBRT for very select patients with extensive preoperative gross extrathyroidal extension or large-volume, multicompartment macroscopic lymph node involvement [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The lack of randomized trials makes it difficult to provide definitive recommendations with regard to the use of EBRT as adjuvant therapy. We feel that EBRT in this setting may improve locoregional control but are not convinced that there is an overall survival benefit [
         <a href="#rid58">
          58
         </a>
         ]. Furthermore, the potential benefits of improved locoregional control must be weighed against the wide range of acute and chronic toxicities associated with EBRT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a retrospective study of 51 patients with persistently elevated calcitonin (ranging from 540 to 400,000 pg/mL) and no evidence of residual disease, the local relapse rate was significantly lower in those who were treated with radiation therapy because of advanced local disease at presentation (29 versus 59 percent) [
         <a href="#rid59">
          59
         </a>
         ]. There was no difference in 10-year survival between the two groups (72 versus 60 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small-volume residual disease outside of cervical lymph nodes (thyroid bed or soft tissue metastases)
         </strong>
         – Small-volume disease outside of cervical lymph nodes is usually the result of gross extrathyroidal extension into major structures in the neck, and it often reflects microscopic disease remaining after all macroscopic disease has been surgically resected (R1 resection). Usually, this is microscopic disease involving muscle, airway, esophagus, soft tissues in the neck, or thyroid bed. As these patients are at high risk of locoregional recurrence, we suggest EBRT as adjuvant therapy in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Structurally identifiable small-volume disease can also be a manifestation of an early soft tissue recurrence of MTC, in which case the initial treatment option would be surgical resection, usually followed by EBRT (or occasionally EBRT alone if surgery is unlikely to be successful or likely to result in unacceptable morbidity).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Retrospective analyses have suggested that radiotherapy may prolong the interval until disease progression or recurrence in some patients. In one retrospective series, as an example, the 10-year rate of control of local and regional disease was 86 percent in patients with residual microscopic neck disease who received postoperative radiotherapy versus 52 percent in those who were not treated [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small-volume lymph node metastases
         </strong>
         – For most MTC patients with persistent, asymptomatic small-volume locoregional disease (subcentimeter lymph node metastases), we suggest active surveillance as the best management option. Reoperation is frequently not curative and can be associated with morbidity (ie, hypoparathyroidism, injury to recurrent laryngeal nerve or accessory nerve). In addition, observation of asymptomatic, stable lymph node metastases is nearly always recommended if the basal serum calcitonin is &gt;1000 pg/mL or if more than five metastatic lymph nodes were removed with a previous surgery as reoperation is almost never curative in these settings [
         <a href="#rid1">
          1
         </a>
         ]. Patients are followed with serial cross-sectional imaging at 6- to 12-month intervals, and surgical intervention is reserved for patients that have documented structural disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small-volume distant metastases
         </strong>
         – Similar to asymptomatic small-volume lymph node metastases, small-volume distant metastases (subcentimeter metastatic foci) are usually followed with observation. It is not uncommon for small pulmonary and liver metastases to remain asymptomatic and progress very slowly (or not all) over many years.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18453273">
         <span class="h3">
          Large volume or symptomatic
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Macroscopic gross residual disease in the thyroid bed or cervical soft tissue metastases
         </strong>
         – If the gross residual disease is confirmed to be unresectable or if the patient/treatment team agree that a complete surgical resection would produce unacceptable morbidity, we suggest EBRT to improve locoregional control. While systemic therapy (such as multitargeted kinase inhibitors or selective RET inhibitors in RET-mutated tumors) can be considered in this setting, our preference is to use EBRT to achieve local regional control as the initial treatment unless there are other pressing indications to begin systemic therapy [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic or large-volume locoregional lymph node disease
         </strong>
         – Resection of large-volume locoregional lymph node disease may be necessary to prevent invasion into surrounding major structures. Occasionally, lymph node metastases can present as painful lesions that can be readily palliated with surgical resection. However, since additional surgery rarely achieves a biochemical cure if the basal serum calcitonin is &gt;1000 pg/mL or if more than five metastatic lymph nodes were removed with a previous surgery, cautious observation or systemic therapies (tyrosine kinase inhibitors) can be considered for asymptomatic large-volume lymph node metastases detected in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic or large-volume distant metastasis
         </strong>
         – Rather than immediately initiating systemic therapy, we prefer to treat individual (or a few) isolated symptomatic or large-volume distant metastases with locally directed therapies such as surgical resection, EBRT, embolization, or radiofrequency ablation. For patients with symptomatic or progressive metastatic disease that cannot be effectively treated by locally directed therapies, systemic treatment with biologic response modifiers (ie, multitargeted kinase inhibitors or selective RET inhibitors in RET-mutated tumors) may improve progression-free survival. Molecular characterization of the primary tumor or metastatic foci is recommended prior to initiating systemic therapy in order to identify patients with sporadic MTC that may harbor a somatic
         <em>
          RET
         </em>
         mutation, which would likely respond to specific RET inhibitors. Kinase inhibitors are reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Locally directed therapies are recommended in the following clinical settings:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large-volume solitary metastatic lesions in the lung, liver, or brain should be considered for surgical resection. Radiofrequency ablation may be an option for smaller peripheral lung metastases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oligometastatic lesions in the bone can be treated with surgical resection, EBRT, embolization, and/or antiresorptive agents (eg, bisphosphonates,
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         ). EBRT is often utilized to palliate painful bone metastases or decrease the risk of fracture from progressive growth of a bone metastasis. (See
         <a class="medical medical_review" href="/z/d/html/115410.html" rel="external">
          "Overview of therapeutic approaches for adult patients with bone metastasis from solid tumors", section on 'General approach to the patient'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multiple liver metastases may be amenable to localized therapies such as transarterial chemoembolization or, less commonly, percutaneous ethanol ablation or radiofrequency ablation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin metastases are usually treated with surgical resection or, less commonly, with EBRT.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18453027">
         <span class="h3">
          Palliation of the symptoms associated with hormonal excess
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diarrhea and ectopic Cushing syndrome, the most common hormonal excess syndromes, are usually seen in the setting of large-volume persistent/recurrent disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diarrhea
         </strong>
         – Usually associated with large-volume liver metastases, the diarrhea associated with MTC can have a major impact on quality of life. Dietary measures such as avoiding alcohol intake and maintaining a diet that limits high-fiber foods can be augmented with antimotility agents (
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         , diphenoxylate/
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         ) as first-line therapy. Somatostatin analogs may provide modest symptomatic improvement in some patients. In selected patients, debulking of large tumor deposits with surgery or chemoembolization may improve diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ectopic Cushing syndrome
         </strong>
         – We prefer
         <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">
          vandetanib
         </a>
         (prior to medical or surgical adrenalectomy) as first-line therapy for ectopic Cushing syndrome, based on reports of a very rapid decline in serum cortisol levels in several patients [
         <a href="#rid61">
          61,62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy", section on 'Vandetanib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because Cushing syndrome is associated with severe and debilitating side effects, treatment should be strongly considered even in the setting of large-volume persistent/recurrent disease. In our experience, medical therapy (
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">
          mitotane
         </a>
         ,
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         ) is generally suboptimally effective and poorly tolerated. Tumor debulking is unlikely to be effective as these patients usually have multiple sites of large-volume disease. Conversely, we find that bilateral adrenalectomy is well tolerated and effective but challenging, given the comorbidities associated with large-volume MTC and hypercortisolism. (See
         <a class="medical medical_review" href="/z/d/html/174.html" rel="external">
          "Overview of the treatment of Cushing syndrome", section on 'Nonresectable tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2736614">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Age and stage of disease at the time of diagnosis have been shown to be important factors that influences prognosis [
         <a href="#rid1">
          1,6
         </a>
         ]; the 5- and 10-year disease-free survival rates are higher among patients 40 years old or less as compared with patients over age 40 years (95 versus 65 percent and 75 versus 50 percent, respectively) [
         <a href="#rid6">
          6,63
         </a>
         ]. However, another study found no effect of age if survival was compared with the expected mortality rates in the general population [
         <a href="#rid64">
          64
         </a>
         ]. The 10-year survival rates for patients with stages I, II, III, and IV medullary thyroid cancer (MTC) are 100, 93, 71, and 21 percent, respectively [
         <a href="#rid1">
          1,11
         </a>
         ].
        </p>
        <p>
         A nomogram that integrates age, sex, postoperative calcitonin, vascular invasion, and TNM (tumor, node, metastasis) status has been developed that can be used to easily predict cause-specific mortality [
         <a href="#rid65">
          65
         </a>
         ]. Furthermore, using an approach previously validated in non-MTC [
         <a href="#rid66">
          66
         </a>
         ], a response to the therapy stratification system was shown to have a higher proportion of variance explained for predicting clinical outcomes than the TNM/American Joint Committee on Cancer (AJCC) system [
         <a href="#rid10">
          10,13
         </a>
         ].
        </p>
        <p>
         Calcitonin and carcinoembryonic antigen (CEA) doubling times provide sensitive markers for progression and aggressiveness of metastatic MTC. Calcitonin doubling times less than 6 to 12 months are associated with poor survival, while doubling times &gt;24 months are associated with a very favorable prognosis [
         <a href="#rid40">
          40,41
         </a>
         ]. Furthermore, a tumor volume doubling time of ≤1 year in pulmonary metastases is associated with poorer overall survival [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Controlling for the effect of age, the prognosis of patients with inherited disease is probably similar to those with sporadic disease [
         <a href="#rid68">
          68,69
         </a>
         ]. Specific germline mutations in
         <em>
          RET
         </em>
         predict the aggressiveness of the tumor [
         <a href="#rid1">
          1
         </a>
         ]. As an example, patients with multiple endocrine neoplasia type 2B (MEN2B; germline
         <em>
          RET
         </em>
         mutation codon 918) are more likely to have invasive disease and therefore a worse prognosis than those with either classical multiple endocrine neoplasia type 2A (MEN2A) or familial MTC [
         <a href="#rid68">
          68
         </a>
         ]. In some [
         <a href="#rid22">
          22-24
         </a>
         ], but not other [
         <a href="#rid25">
          25
         </a>
         ], studies, tumors with an identifiable
         <em>
          RET
         </em>
         mutation (ie, a somatic mutation) had a more aggressive course than those without a mutation.
        </p>
        <p>
         Other factors that may predict a poor prognosis include cellular heterogeneity, paucity of tumor immunostaining for calcitonin [
         <a href="#rid70">
          70
         </a>
         ], prominent tissue immunostaining for galectin-3 [
         <a href="#rid71">
          71
         </a>
         ] or immunostaining for CEA associated with scant or absent tissue staining for calcitonin [
         <a href="#rid72">
          72
         </a>
         ], high preoperative serum CEA [
         <a href="#rid73">
          73
         </a>
         ], a less than 10-fold increase in preoperative calcitonin levels after stimulation with pentagastrin [
         <a href="#rid74">
          74
         </a>
         ], an elevated procalcitonin-to-calcitonin ratio [
         <a href="#rid75">
          75
         </a>
         ], and a rising CEA level associated with a stable or declining calcitonin level.
        </p>
        <p class="headingAnchor" id="H70472181">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117633.html" rel="external">
          "Society guideline links: Medullary thyroid cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12719789">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative evaluation
         </strong>
         – For patients with newly diagnosed medullary thyroid cancer (MTC), preoperative evaluation should include measurement of serum calcitonin, carcinoembryonic antigen (CEA), ultrasonography of the neck (if not already performed), genetic testing for germline
         <em>
          RET
         </em>
         mutations (can be performed pre- or postoperatively), and, in all patients who have either unknown
         <em>
          RET
         </em>
         mutation status or a germline
         <em>
          RET
         </em>
         mutation, biochemical evaluation for coexisting tumors (especially pheochromocytoma) (
         <a class="graphic graphic_algorithm graphicRef102747" href="/z/d/graphic/102747.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with local lymph node metastases on ultrasound or with preoperative serum basal calcitonin &gt;500 pg/mL (indicating high risk of local or distant metastatic disease), additional imaging is required to assess for metastatic disease. (See
         <a class="local">
          'Preoperative evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7848.html" rel="external">
          "Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical approach
         </strong>
         – For patients with sporadic MTC, we recommend total thyroidectomy rather than lobectomy for initial therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Owing to the multicentric and bilateral nature of hereditary MTC (and its precursor C cell hyperplasia), total thyroidectomy is the only way to cure hereditary MTC. (See
         <a class="local">
          'Surgical approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">
          "Approach to therapy in multiple endocrine neoplasia type 2", section on 'Medullary thyroid cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with MTC confined to the neck and no evidence of involved cervical lymph nodes on preoperative ultrasound, we routinely perform bilateral dissection of the central lymph node compartment without prophylactic lateral neck dissection. For patients with evidence of central cervical lymph node involvement, dissection of the involved lateral neck compartment is also performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with locally advanced or metastatic disease, total thyroidectomy with resection of involved lymph node compartments is performed in most patients. However, since the goals of surgery are largely palliative in this setting, a less aggressive approach to both the primary tumor and to locoregional metastases may be warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative
         </strong>
         <strong>
          levothyroxine
         </strong>
         <strong>
          replacement
         </strong>
         – Thyroxine (
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         , T4) therapy should be started immediately after surgery. The goal of T4 therapy is to restore and maintain euthyroidism. Suppression of serum thyroid-stimulating hormone (TSH) concentrations is not indicated in patients with MTC, because C cells are not TSH responsive. Similarly, adjuvant therapy with radioiodine is not indicated, because the tumor cells do not concentrate iodine. (See
         <a class="local">
          'Thyroxine therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative assessment
         </strong>
         – Serum calcitonin and CEA should be measured two to three months after surgery to detect the presence of residual disease. (See
         <a class="local">
          'Serum calcitonin and CEA measurement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calcitonin
         </strong>
         <strong>
          undetectable
         </strong>
         – For patients with undetectable postoperative calcitonin levels, we measure serum calcitonin and CEA levels twice yearly for two years and then yearly if values are stable. We typically obtain a neck ultrasound 6 to 12 months postoperatively to establish a baseline. Serial ultrasound evaluations are not required in patients with undetectable postoperative calcitonin levels. (See
         <a class="local">
          'Undetectable calcitonin and normal CEA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calcitonin
         </strong>
         <strong>
          persistently elevated
         </strong>
         – For patients with persistent hypercalcitoninemia, further evaluation depends upon the magnitude of the elevation in the serum calcitonin concentration and the calcitonin and CEA doubling times (
         <a class="graphic graphic_algorithm graphicRef102746" href="/z/d/graphic/102746.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Persistent hypercalcitoninemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Calcitonin
         </strong>
         <strong>
          &lt;150 pg/mL
         </strong>
         – Patients with postoperative calcitonin levels that are detectable but less than 150 pg/mL (two to six months after surgery) should have neck imaging (ultrasound with or without computed tomography [CT] or magnetic resonance imaging [MRI]) to identify persistent locoregional disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Calcitonin
         </strong>
         <strong>
          ≥150 pg/mL
         </strong>
         – Patients with postoperative calcitonin levels that are ≥150 pg/mL (two to six months after surgery) should undergo additional imaging (CT or MRI of neck, chest, and abdomen; bone scan or bone MRI in patients suspected of having skeletal metastases) to identify possible distant metastases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of persistent or recurrent disease
         </strong>
         – Treatment options for patients with recurrent/residual disease include observation/active surveillance, surgical resection, external beam radiation therapy (EBRT), and other directed therapies (such as radiofrequency ablation, cryoablation, embolization) or systemic therapies. Choice of therapy depends upon clinical factors,
         <em>
          RET
         </em>
         mutational status, and the potential morbidities of therapy. (See
         <a class="local">
          'Management of persistent/recurrent disease'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network Guidelines https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (Accessed on March 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen R, Campos JM, Salaün C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 2000; 85:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003; 88:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duh QY, Sancho JJ, Greenspan FS, et al. Medullary thyroid carcinoma. The need for early diagnosis and total thyroidectomy. Arch Surg 1989; 124:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999; 230:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 2008; 95:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsey SC, Ganly I, Palmer F, Tuttle RM. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 2015; 25:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 1998; 48:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franc S, Niccoli-Sire P, Cohen R, et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2001; 55:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuttle RM, Ganly I. Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. Oral Oncol 2013; 49:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boostrom SY, Grant CS, Thompson GB, et al. Need for a revised staging consensus in medullary thyroid carcinoma. Arch Surg 2009; 144:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsang V. The Role of a Neoadjuvant RET inhibitor in Medullary Thyroid Cancer. Clinical Thyroidology 2023; 35:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contrera KJ, Gule-Monroe MK, Hu MI, et al. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid 2023; 33:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walgama E, Busaidy N, Zafereo M. Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer. Endocrinol Metab Clin North Am 2022; 51:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grasic Kuhar C, Lozar T, Besic N, Music Marolt M. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia. Adv Ther 2021; 38:5684.
          </a>
         </li>
         <li class="breakAll">
          Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer. Clinicaltrials.gov. U.S. National Library of Medicine. January 26, 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT04759911 (Accessed on April 10, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92:4185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983; 57:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zedenius J, Larsson C, Bergholm U, et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 1995; 80:3088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996; 81:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008; 93:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1996; 44:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engelbach M, Görges R, Forst T, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000; 85:1890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JH, Lindsey SC, Camacho CP, et al. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer. Clin Endocrinol (Oxf) 2015; 83:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC. Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 1979; 43:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faggiano A, Milone F, Ramundo V, et al. A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. J Clin Endocrinol Metab 2010; 95:E32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fugazzola L, Pinchera A, Luchetti F, et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994; 9:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girelli ME, Dotto S, Nacamulli D, et al. Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 1994; 80:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brauckhoff M, Gimm O, Brauckhoff K, et al. Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma. Langenbecks Arch Surg 2001; 386:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismailov SI, Piulatova NR. Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 2004; 11:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade F, Rondeau G, Boucai L, et al. Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer. Arch Endocrinol Metab 2019; 63:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson CE, Talpos GB, Kambouris A, et al. The clinical course after definitive operation for medullary thyroid carcinoma. Surgery 1983; 94:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells SA Jr, Dilley WG, Farndon JA, et al. Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med 1985; 145:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scopsi L, Sampietro G, Boracchi P, et al. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 1996; 78:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996; 77:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007; 33:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90:6077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong SC, Schöder H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauhanen S, Schalin-Jäntti C, Seppänen M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med 2011; 52:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archier A, Heimburger C, Guerin C, et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2016; 43:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beheshti M, Pöcher S, Vali R, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 2009; 19:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treglia G, Castaldi P, Villani MF, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012; 39:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castroneves LA, Coura Filho G, de Freitas RMC, et al. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases. J Clin Endocrinol Metab 2018; 103:3250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran K, Khan S, Taghizadehasl M, et al. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med 2015; 18:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conry BG, Papathanasiou ND, Prakash V, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Łapińska G, Bryszewska M, Fijołek-Warszewska A, et al. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl Med Rev Cent East Eur 2011; 14:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozkan ZG, Kuyumcu S, Uzum AK, et al. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun 2015; 36:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamaga LYI, Cunha ML, Campos Neto GC, et al. 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging 2017; 44:1695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berná L, Cabezas R, Mora J, et al. 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 1995; 144:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udelsman R, Ball D, Baylin SB, et al. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid. Surgery 1993; 114:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gotthardt M, Béhé MP, Beuter D, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006; 33:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelmoumene N, Schlumberger M, Gardet P, et al. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer 1994; 69:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990; 212:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fersht N, Vini L, A'Hern R, Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 2001; 11:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groen AH, Beckham TH, Links TP, et al. Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma. J Surg Oncol 2020; 121:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baudry C, Paepegaey AC, Groussin L. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med 2013; 369:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 2013; 19:4239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984; 63:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Groot JW, Plukker JT, Wolffenbuttel BH, et al. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 2006; 65:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho AS, Wang L, Palmer FL, et al. Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer. Ann Surg Oncol 2015; 22:2700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh T, Yeung M, Sherman EJ, et al. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. Thyroid 2020; 30:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Riordain DS, O'Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 1994; 116:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988; 67:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lippman SM, Mendelsohn G, Trump DL, et al. The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. J Clin Endocrinol Metab 1982; 54:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faggiano A, Talbot M, Lacroix L, et al. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol (Oxf) 2002; 57:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer 1984; 54:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 2007; 142:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machens A, Hauptmann S, Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? J Clin Endocrinol Metab 2008; 93:2234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter MA, Meier C, Radimerski T, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer 2010; 116:31.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2190 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25810047" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25810047" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690910" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20339026" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12727956" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699905" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2802985" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Medullary thyroid carcinoma. The need for early diagnosis and total thyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561095" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Surgical strategy for the treatment of medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18300267" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prediction of lateral lymph node metastases in medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25338223" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Response to initial therapy predicts clinical outcomes in medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9578814" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeursàcalcitonine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11589685" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23601563" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19620547" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Need for a revised staging consensus in medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The Role of a Neoadjuvant RET inhibitor in Medullary Thyroid Cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36503246" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35662447" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34674146" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34674146" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17726071" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6853671" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Radioactive iodine in the treatment of medullary carcinoma of the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7559902" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8636377" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18073307" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8729519" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10843170" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25376110" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/427724" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Medullary thyroid carcinoma: importance of serial serum calcitonin measurement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20534767" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8051432" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8016900" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11735017" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15163310" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Postoperative calcitonin study in medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30916162" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6648816" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The clinical course after definitive operation for medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4015274" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Early diagnosis and treatment of medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8918412" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8608543" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17125960" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16091497" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18230832" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17401085" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22052128" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26497699" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19156423" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22223169" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29846642" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25679074" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19662413" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21751167" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25369749" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of⁶⁸Ga-DOTATATE PET-CT,¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28429044" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7706986" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8256211" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16832634" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8198983" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2222011" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8875751" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12186504" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31733124" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23924025" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23766359" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6503683" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17121523" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Determinants of life expectancy in medullary thyroid cancer: age does not matter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25366585" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24891169" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Update on differentiated thyroid cancer staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32131709" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7985081" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2901430" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6798062" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12460332" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6378353" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17372055" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18364379" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19890958" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
